Leerink Partners downgraded Caribou Biosciences (CRBU) to Market Perform from Outperform, setting a $1 price target. The previous rating was Outperform.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
